PriceTargets.com logo

Biosig Technologies - STEX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $9.00
  • Forecasted Upside: 662.71%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.18 As of 05/1/2026 05:00 PM ET
▲ +0.4148 (54.21%)

This chart shows the closing price for STEX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biosig Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STEX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STEX

Analyst Price Target is $9.00
▲ +662.71% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Biosig Technologies in the last 3 months. The average price target is $9.00, with a high forecast of $9.00 and a low forecast of $9.00. The average price target represents a 662.71% upside from the last price of $1.18.

This chart shows the closing price for STEX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Biosig Technologies. This rating changed within the last month from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/1/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
4/9/2026Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $9.00
1/23/2026Weiss RatingsInitiated CoverageSell (D-)
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Biosig Technologies logo
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
Read More

Today's Range

Now: $1.18
Low: $0.70
High: $1.20

50 Day Range

MA: $1.49
Low: $0.77
High: $2.39

52 Week Range

Now: $1.18
Low: $0.70
High: $14.11

Volume

6,007,630 shs

Average Volume

1,297,323 shs

Market Capitalization

$213.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Biosig Technologies?

The following Wall Street analysts have issued reports on Biosig Technologies in the last twelve months: Needham & Company LLC, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for STEX.

What is the current price target for Biosig Technologies?

0 Wall Street analysts have set twelve-month price targets for Biosig Technologies in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 662.7%. Needham & Company LLC has the highest price target set, predicting STEX will reach $9.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $9.00 for Biosig Technologies in the next year.
View the latest price targets for STEX.

What is the current consensus analyst rating for Biosig Technologies?

Biosig Technologies currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in STEX, but not buy more shares or sell existing shares.
View the latest ratings for STEX.

What other companies compete with Biosig Technologies?

Other companies that are similar to Biosig Technologies include Alpha Tau Medical, Brainsway, SiBone, NeuroPace and Tactile Systems Technology. Learn More about companies similar to Biosig Technologies.

How do I contact Biosig Technologies' investor relations team?

Biosig Technologies' physical mailing address is 55 GREENS FARMS ROAD, WESTPORT, CT, 06880. The company's listed phone number is (203) 409-5444 and its investor relations email address is [email protected]. The official website for Biosig Technologies is biosig.com. Learn More about contacing Biosig Technologies investor relations.